Ipca Laboratories share price
You have to be logged in to add this to Watchlist.- ₹1,458.30(1.00%)May 23, 2025 15:29:55 PM IST
- NSE
- BSE
- Vol : 129.75K (NSE + BSE)Last 20 day avg : 236.00 K
Ipca Laboratories is trading 1.00% upper at Rs 1,458.30 as compared to its last closing price. Ipca Laboratories has been trading in the price range of 1,479.55 & 1,430.20. Ipca Laboratories has given -13.87% in this year & 4.84% in the last 5 days. Ipca Laboratories has TTM P/E ratio 58.95 as compared to the sector P/E of 24.95.There are 13 analysts who have initiated coverage on Ipca Laboratories. There are 4 analysts who have given it a strong buy rating & 6 analysts have given it a buy rating. 0.00 analysts have given the stock a sell rating.The company posted a net profit of 248.14 Crores in its last quarter.Listed peers of Ipca Laboratories include Glenmark Pharmaceuticals (-0.51%), Biocon (-0.78%), Ipca Laboratories (1.00%).The Mutual Fund holding in Ipca Laboratories was at 29.63% in 31 Mar 2025. The MF holding has decreased from the last quarter. The FII holding in Ipca Laboratories was at 10.75% in 31 Mar 2025. The FII holding has decreased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Updated on May 25, 2025, 04:26 AM UTC
- Dividend YieldLower than industry0.27Annual dividends as a percentage of the stock price.
- P/BHigher than historical values5.85The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/EHigher than historical values50.77Price-to-earnings ratio based on trailing 12-month earnings
- BetaLow volatility0.60Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityHigher than industry0.23The debt-to-equity ratio, indicating a company's financial leverage.
- PEG Ratio-The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
|
| ||||
|
| ||||
- Income
- Balance Sheet
- Cash Flow
- Financial
- Valuation
Company is profitable- The company's revenue grew in December quarter by 9.38% from Rs 2245.37 crore to Rs 2052.86 crore, year-on-year
- The company has grown its December quarter profit by 37.95% from Rs 179.88 crore to Rs 248.14 crore, year-on-year
The debt to equity of the company is higher than the industry median- Company can comfortably pay off its interest obligations with its earnings
- R1
- 1,485.87
- R2
- 1,575.18
- R3
- 1,654.77
- S1
- 1,316.97
- S2
- 1,237.38
- S3
- 1,148.07
- Very Bearish
- Bearish
- Neutral
- Very Bullish
- Bullish
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Glenmark Pharmaceuticals | Bearish | 1,423.75 | -0.51 | 40,098.49 | - | 5.11 | 0.18 | 1.93 |
| Biocon | Bearish | 330.65 | -0.78 | 39,697.84 | 42.14 | 1.83 | 0.15 | 59.81 |
| Ipca Laboratories | Moderately Bullish | 1,458.30 | 1.00 | 36,926.90 | 56.47 | 5.85 | 0.27 | 9.80 |
| Ajanta Pharma | Bearish | 2,567.00 | -0.22 | 32,029.46 | 35.02 | 8.49 | 2.10 | 0.92 |
| Laurus Labs | Neutral | 592.60 | 0.36 | 31,956.10 | 89.35 | 7.15 | 0.20 | 15.82 |
- Promoter(s) holding is moderate at 44.72%
- Promoter(s) have decreased the stake in the company in last 12 months
- FIIs are invested in this company
- FIIs holding has decreased by 0.31 percentage points from previous quarter
- Mutual Funds holding is constant over the last quarter at 29.63%
- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2025-05-29 | Audited Results & Final Dividend |
| 2025-02-13 | Quarterly Results |
| 2024-11-14 | Quarterly Results & Interim Dividend |
| 2024-09-30 | Others |
| 2024-08-13 | Quarterly Results |
- IndustryBiotechnology & Drugs
- ISININE571A01038
- BSE Code524494
- NSE CodeIPCALAB
Ipca Laboratories is trading at 1458.30 as on Fri May 23 2025 09:59:55. This is 1.00% upper as compared to its previous closing price of 1443.90.
The market capitalization of Ipca Laboratories is 36926.90 Cr as on Fri May 23 2025 09:59:55.
The average broker rating on Ipca Laboratories is Buy. The breakup of analyst rating is given below -
- 4 analysts have given a strong buy rating
- 6 analysts have given a buy rating
- 3 analysts have given a hold rating
- 0.00 analysts have given a sell rating
- 0.00 analysts have given a strong sell rating
The 52 wk high for Ipca Laboratories is 1757.65 whereas the 52 wk low is 1060.95
Ipca Laboratories can be analyzed on the following key metrics -
- TTM P/E: 58.95
- Sector P/E: 24.95
- Dividend Yield: 0.27%
- D/E ratio: -
Ipca Laboratories reported a net profit of 547.35 Cr in 2024.
The Mutual Fund Shareholding was 29.63% at the end of 31 Mar 2025.